2003 - Robert J. and Claire Pasarow Foundation Medical Research Award
2001 - Benjamin Franklin Medal, Franklin Institute
1999 - J. Allyn Taylor International Prize in Medicine, Robarts Research Institute
1990 - Member of the National Academy of Sciences
1990 - Member of the National Academy of Medicine (NAM)
1988 - Fellow of the American Association for the Advancement of Science (AAAS)
Member of the Association of American Physicians
His primary areas of study are Angiogenesis, Neovascularization, Cancer research, Pathology and Internal medicine. His Angiogenesis study incorporates themes from Basic fibroblast growth factor, Immunology and Cell biology. His biological study spans a wide range of topics, including Endothelial stem cell, Vascular endothelial growth factor A, Cornea, Endothelium and In vivo.
His Cancer research research is multidisciplinary, incorporating elements of Cancer and Angiogenic Switch. The Immunohistochemistry research Judah Folkman does as part of his general Pathology study is frequently linked to other disciplines of science, such as Intussusceptive angiogenesis, therefore creating a link between diverse domains of science. His Internal medicine study integrates concerns from other disciplines, such as Endocrinology and Oncology.
Angiogenesis, Cancer research, Pathology, Internal medicine and Neovascularization are his primary areas of study. His studies in Angiogenesis integrate themes in fields like Endothelial stem cell, Cancer, Immunology and Basic fibroblast growth factor. Judah Folkman combines subjects such as Endothelium and Angiogenic Switch with his study of Cancer research.
His Pathology research is multidisciplinary, relying on both Tumor angiogenesis and Transplantation. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology, Endocrinology and Oncology. In his study, In vitro is strongly linked to In vivo, which falls under the umbrella field of Neovascularization.
Judah Folkman mostly deals with Angiogenesis, Cancer research, Internal medicine, Cancer and Pathology. His research in Angiogenesis intersects with topics in Platelet and Immunology. His Cancer research research includes themes of Endothelial stem cell, Cell growth and Epidermal growth factor receptor.
His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Endocrinology, Surgery and Oncology. His Cancer study combines topics in areas such as Surgical oncology, Disease and Chemotherapy. His Pathology research incorporates themes from Hematology, Transcriptome and Transplantation.
Judah Folkman focuses on Angiogenesis, Cancer research, Cancer, Immunology and Internal medicine. His study in Angiogenesis is interdisciplinary in nature, drawing from both Tumor progression, Angiogenic Switch and Pathology. His research integrates issues of Endothelial stem cell and Epidermal growth factor receptor in his study of Cancer research.
He has included themes like Bevacizumab, Glioma, Angiostatin, Sunitinib and Growth factor receptor in his Immunology study. The study incorporates disciplines such as Endocrinology and Oncology in addition to Internal medicine. As part of the same scientific family, he usually focuses on Neovascularization, concentrating on Angiogenesis inhibitor and intersecting with Cell biology, Stromal cell and Bone marrow.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Tumor Angiogenesis: Therapeutic Implications
The New England Journal of Medicine (1971)
Angiogenesis in cancer, vascular, rheumatoid and other disease
Nature Medicine (1995)
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
Douglas Hanahan;Judah Folkman;Judah Folkman.
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.
Noel Weidner;Joseph P. Semple;William R. Welch;Judah Folkman.
The New England Journal of Medicine (1991)
What is the evidence that tumors are angiogenesis dependent
Journal of the National Cancer Institute (1990)
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.
Michael S O'Reilly;Thomas Boehm;Yuen Shing;Naomi Fukai.
Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma
Michael S. O'Reilly;Michael S. O'Reilly;Lars Holmgren;Lars Holmgren;Yuen Shing;Yuen Shing;Catherine Chen;Catherine Chen.
Transplacental carcinogenesis by stilbestrol
The New England Journal of Medicine (1971)
Role of angiogenesis in tumor growth and metastasis
Seminars in Oncology (2002)
Thalidomide is an inhibitor of angiogenesis.
Robert J. D'Amato;Michael S. Loughnan;Evelyn Flynn;Judah Folkman.
Proceedings of the National Academy of Sciences of the United States of America (1994)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: